about
Inactivation of the HIF-1α/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidantsAutocrine and paracrine angiopoietin 1/Tie-2 signaling promotes muscle satellite cell self-renewalImaging Modalities to Assess Oxygen Status in GlioblastomaTargeting the erythropoietin receptor on glioma cells reduces tumour growthThe impact of erythropoietin on short-term changes in phosphorylation of brain protein kinases in a rat model of traumatic brain injury.IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.Diffusion tensor imaging of diffuse axonal injury in a rat brain trauma model.[(18)F]-fluoro-L-thymidine PET and advanced MRI for preoperative grading of gliomas.Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.TNF receptor I sensitizes neurons to erythropoietin- and VEGF-mediated neuroprotection after ischemic and excitotoxic injuryHuman leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-γ treatments: results from a multicentric study.Angiopoietin-2 is vasoprotective in the acute phase of cerebral ischemiaMRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor modelIn vivo relationship between hypoxia and angiogenesis in human glioblastoma: a multimodal imaging study.Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental models of human glioma.Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.Angiopoietin-2 regulates cortical neurogenesis in the developing telencephalon.Assessment of blood volume, vessel size, and the expression of angiogenic factors in two rat glioma models: a longitudinal in vivo and ex vivo study.In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma.FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas.M2 macrophages are more resistant than M1 macrophages following radiation therapy in the context of glioblastoma.Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis.FLIP(L) protects neurons against in vivo ischemia and in vitro glucose deprivation-induced cell death.Time- and cell type-specific induction of platelet-derived growth factor receptor-beta during cerebral ischemia.Synergistic effects of CoCl(2) and ROCK inhibition on mesenchymal stem cell differentiation into neuron-like cells.Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat.Erratum to "In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma" [NeuroImage 37S1 (2007) S47-S58].A Facile Route toward the Increase of Oxygen Content in Nanosized Zeolite by Insertion of Cerium and Fluorinated Compounds.3D Registration of mpMRI for Assessment of Prostate Cancer Focal Therapy.[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis.[F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: Comparative analysis with [F]FDG in human xenograft modelsReduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative*VEGF-Induced BBB Permeability is Associated with an MMP-9 Activity Increase in Cerebral ischemia: Both Effects Decreased by ANG-1A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke.In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of gliomaVCAM-1 targeted alpha-particle therapy for early brain metastases64Cu-ATSM/64Cu-Cl2 and their relationship to hypoxia in glioblastoma: a preclinical studyPotential for Nuclear Medicine Therapy for Glioblastoma TreatmentComparison between MRI-derived ADC maps and 18FLT-PET in pre-operative glioblastomaHypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma
P50
Q24295051-4BED5F36-9BCB-4A59-B723-8E6BD8F3A8B6Q24313467-E1858691-B13F-4D13-9254-EC22C5AC9B91Q26782708-D1947E71-3594-4767-8DE0-0501F99DF38BQ28584214-D463B39A-22DD-4776-BBD9-128F6352A187Q33509004-7B661697-C6A0-4863-A71A-25805E7408FCQ33660428-59FCF107-8584-43FA-B5FE-2C24D7A82990Q33913723-5898C2E8-4691-488D-BC14-7CF279273C1DQ35760788-895D96AE-2E5C-4043-96D0-EB48CFDDCEA5Q36500372-33C238C4-7FA9-4B0C-88AA-00A8A4551FE5Q36545939-B25F5520-0D40-45F8-9012-7E95C14751D1Q36582874-40A9A79F-9962-4047-8EF1-8B547BF0B567Q36655378-4127B7B3-0851-45E0-92F7-148B4C0E46C0Q37395338-B6E5B430-91BD-401D-8429-954F67B59ACBQ38735472-8C324770-BD81-4C65-A1D6-71D3B711CB68Q39469151-09131927-4DE7-4B19-BC23-670FE61A5DC2Q39489907-8AFDC290-1508-4A52-8811-04CF6F243364Q39624603-B0A73FC0-CEE9-42E5-91BC-2A372AA77B89Q39963091-BC2044FF-E095-4C3C-BA6D-01A986DE1642Q40111538-6F5292CB-146A-410D-80F9-C499BB6212C6Q41581761-B2222988-0849-4DE3-BB9A-17E19FA636AFQ42700764-BB25332D-5DC9-4CC4-AC68-147FA9B9ADEAQ44270070-5253128F-671B-4D80-A016-2EB4C2531CECQ48130829-B7CCC946-6E62-43B3-87F2-C28EAE528C82Q48308816-7398F1C1-EFE3-423F-A3D6-EE0D84C01DCCQ48497907-39745CB7-085C-42A2-AE0A-FB5B7FCBADD2Q48579211-15B64C08-7C4B-4C59-9DA7-3E4CEE1CC890Q48883857-A7D066D3-78B2-4329-B075-FA7E375325F3Q49828185-530F8827-5215-4DE2-8818-C1322D8DA553Q50085940-2C414C07-E472-4A05-A397-C044D078D8BCQ50790940-923C2326-69C5-4683-A261-2A78B5F26C89Q58788935-ACF57A68-3F6E-49BA-BB1A-46C3981DA141Q63966762-8B6DFB3D-272D-40E4-BCBF-E56E8EEAC98FQ63966767-BB21496C-B150-4B7C-8810-A4A52E67AFFFQ64912083-17247368-FF6C-4F33-9F46-699BAEA3CB88Q81164931-7F19E715-C19C-4E4E-85EE-8819F42ED63DQ90184977-0CBE07C0-9125-482D-8750-C4F45BBC1026Q92136818-94D0CFF4-9BA2-41E1-8196-BC7165639621Q92237972-17491275-9EDE-4AED-A2A5-AACB6BFEA168Q92959776-BC8898E5-79C2-47C8-A26C-150DC4A0C48EQ93091117-FE2DECDE-2FAC-41D5-B0FE-51F0F590BFDC
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-0355-0270
@en
name
Samuel Valable
@ast
Samuel Valable
@en
Samuel Valable
@es
Samuel Valable
@nl
type
label
Samuel Valable
@ast
Samuel Valable
@en
Samuel Valable
@es
Samuel Valable
@nl
prefLabel
Samuel Valable
@ast
Samuel Valable
@en
Samuel Valable
@es
Samuel Valable
@nl
P106
P21
P31
P496
0000-0003-0355-0270